Johnson & Johnson (JNJ) to Accelerate Development of Ebola Vaccine

Shares of Johnson & Johnson (JNJ) were up +0.03 or +0.03 percent to $103.79 per share in premarket trading early Thursday, after news that the company will fast track the development of a new combination vaccine regimen against the Ebola virus. Johnson & Johnson stock closed at $103.76 in Wednesday’s regular trading session. New Brunswick, Read the full article... Read the rest of Johnson & Johnson (JNJ) to Accelerate Development of Ebola Vaccine at InvestorGuide.com .